gsk201103116k2.htm
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending March 2011
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
Directorate Changes
Further to the announcement made on 4th March 2011 regarding the appointments of Ms Judy Lewent and Ms Stacey Cartwright as Non-Executive Directors with effect from 1 April 2011, the Company confirms that there are no further disclosures to be made in accordance with Listing Rule 9.6.13R.
The Company lists below details of their interests in the Ordinary shares of GlaxoSmithKline plc:
| |
Number of Ordinary Shares
|
|
Ms J Lewent
|
-
|
|
Ms S L Cartwright
|
121
|
V A Whyte
Company Secretary
11 March 2011
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: March 11, 2011
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc